Logo

REGN

Regeneron Pharmaceuticals, Inc.

REGN

Regeneron Pharmaceuticals, Inc. • NASDAQ
$780.19 ▼ -0.56% (-4.42)
Market Cap $80.58 B
52w High $800.99
52w Low $476.49
Dividend Yield 3.52%
P/E 18.69
Volume 406.79K
Outstanding Shares 103.28M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.754B ▲ $2.206B ▲ $1.46B ▲ 38.889% ▲ $14.09 ▲ $1.919B ▲
Q2-2025 $3.676B ▲ $2.066B ▲ $1.392B ▲ 37.86% ▲ $13.24 ▲ $1.657B ▲
Q1-2025 $3.029B ▼ $1.973B ▼ $808.7M ▼ 26.701% ▲ $7.58 ▼ $1.041B ▼
Q4-2024 $3.789B ▲ $2.234B ▲ $917.7M ▼ 24.219% ▼ $8.53 ▼ $1.095B ▼
Q3-2024 $3.721B $2.05B $1.341B 36.031% $12.4 $1.629B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.444B ▲ $40.169B ▲ $9.212B ▲ $30.958B ▲
Q2-2025 $7.47B ▼ $38.219B ▲ $8.28B ▲ $29.939B ▲
Q1-2025 $8.349B ▼ $37.545B ▼ $8.158B ▼ $29.388B ▲
Q4-2024 $9.012B ▼ $37.759B ▲ $8.406B ▲ $29.354B ▲
Q3-2024 $9.796B $37.442B $8.116B $29.326B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.46B ▲ $1.619B ▲ $-402.9M ▲ $-717.9M ▲ $497.5M ▲ $1.417B ▲
Q2-2025 $1.392B ▲ $1.144B ▲ $-1.094B ▼ $-1.128B ▼ $-1.077B ▼ $967.6M ▲
Q1-2025 $808.7M ▼ $1.045B ▼ $647.5M ▲ $-1.089B ▲ $604M ▲ $773.6M ▼
Q4-2024 $917.7M ▼ $1.263B ▼ $350.6M ▲ $-1.135B ▼ $477.2M ▲ $995.8M ▼
Q3-2024 $1.341B $1.291B $-574.4M $-634M $83.6M $1.108B

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Collaboration Revenue
Collaboration Revenue
 $1.61Bn ▲$1.53Bn ▼$1.86Bn ▲$1.97Bn ▲
Product
Product
 $2.00Bn ▲$1.42Bn ▼$1.63Bn ▲$1.59Bn ▼
Product and Service Other
Product and Service Other
 $180.00M ▲$80.00M ▼$180.00M ▲$200.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Regeneron’s revenue has grown meaningfully over the last several years, although it peaked during the pandemic and then reset to a more normal level. Today’s sales are well above pre‑pandemic levels, showing that the core business has expanded even after COVID-related products faded. Profit margins remain very strong for a biotech company, with a large share of revenue turning into operating profit and net income. Earnings per share are high but somewhat bumpy year to year, reflecting shifting product contributions, milestones, and one‑off factors rather than a smooth upward line.

Balance Sheet

Balance Sheet The balance sheet looks solid and conservative. Total assets and shareholders’ equity have climbed steadily, indicating that the company is building its financial base over time. Debt is modest and has not been increasing, which limits financial risk. Cash levels are healthy, though not excessive, and when combined with low leverage, they give Regeneron considerable flexibility to fund research, partnerships, and strategic projects without straining its finances.

Cash Flow

Cash Flow Regeneron generates strong, consistent cash flow from its operations, comfortably covering its investment needs. Free cash flow has remained positive throughout the period, even in years when earnings and revenue have fluctuated. Capital spending is meaningful but still a relatively small slice of the cash the business brings in, suggesting that the company can invest in growth while still building up financial reserves. Overall, cash generation appears to be a key strength and an important buffer against industry and pipeline risk.

Competitive Edge

Competitive Edge Regeneron holds a powerful position in biotechnology, built on a mix of blockbuster drugs, deep scientific expertise, and long‑standing partnerships. Flagship products in eye disease and immunology provide substantial, recurring revenue and reinforce the company’s presence with doctors and payers. Its proprietary antibody platform and genetics capabilities are difficult for rivals to copy, giving it a technological edge and a steady stream of potential new medicines. Competition is intense in all of its major markets, especially as biosimilars and new mechanisms emerge, but Regeneron’s combination of scale, data, and platform technology forms a notable competitive moat.

Innovation and R&D

Innovation and R&D Innovation is the core of Regeneron’s identity. Its VelociSuite and VelocImmune platforms, combined with the Regeneron Genetics Center, create a powerful engine for discovering new antibody drugs and validating targets more quickly and precisely than many peers. The company is pushing aggressively into oncology, advanced bispecific antibodies, obesity combinations that aim to protect muscle mass, and cutting‑edge genetic medicines through high‑profile collaborations. Not every program will succeed—some late‑stage trials have had mixed results—but the breadth and depth of the pipeline reduce dependence on any single asset and support a long runway of potential future launches.

Summary

Regeneron is a large, profitable biotech company with strong margins, a robust balance sheet, and reliable cash generation. Revenue and earnings spiked during the pandemic and then normalized, but the underlying business today is clearly larger and stronger than before that period. Its competitive position is anchored in differentiated technologies, blockbuster products, and an unusually productive in‑house R&D engine. The main risks center on clinical and regulatory outcomes, future competition (including biosimilars and new obesity and oncology entrants), and the need to keep replacing aging products with new ones. Overall, its financial strength and innovation capabilities place it among the more established and resilient players in biotechnology, while still carrying the typical uncertainties of a research‑driven business.

NEWS

November 25, 2025 · 1:00 AM UTC

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Read more

November 19, 2025 · 4:10 PM UTC

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Read more

November 19, 2025 · 7:00 AM UTC

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Read more

November 13, 2025 · 7:00 AM UTC

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Read more

November 7, 2025 · 8:00 AM UTC

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Read more